Semax + Selank Blend
Also referenced as: Semax 10 mg + Selank 10 mg, Semax/Selank stack
A combination research vial pairing two Russian nootropic and anxiolytic peptides, commonly supplied as 10 mg of each.
- Evidence grade
- DPreclinical Research
Preclinical Research
- Regulatory status
- Research Use Only
Neither peptide is approved in the United States or European Union. Both are registered medicines in Russia. Sold internationally as research-use-only material.
- Human data
- Limited
No registered clinical trials identified
- Last reviewed
- September 14, 2026
Overview
This blend pairs Semax, an ACTH(4-10) analogue studied for cognitive and neuroprotective effects, with Selank, a tuftsin analogue studied for anxiety. Each has its own guide on this site.
The stated rationale is complementary effects on attention and anxiety. That combination has not been evaluated in a controlled trial, and most supporting literature for each peptide is Russian-language and methodologically limited.
Commonly supplied for research as a vial containing 10 mg of each compound.
Why It's Being Studied
- Attention, memory and cognitive performance.
- Anxiety and stress-related symptoms.
- Neuroprotection after ischaemic events, where Semax has Russian clinical use.
- BDNF and monoamine signalling in animal models.
Mechanism of Action
One peptide is studied for attention and brain protection, the other for anxiety. The blend puts both in one vial.
Semax is a heptapeptide analogue of ACTH(4-10) lacking corticotropic activity, reported to raise BDNF and NGF expression in the hippocampus and modulate dopaminergic and serotonergic transmission. Selank is a synthetic analogue of the immunomodulatory peptide tuftsin, reported to influence GABAergic and serotonergic signalling and enkephalinase activity. No combined neuropharmacology has been published.
Research Areas & Routes Studied
- Cognition
- Anxiety
- Neuroprotection
- Stress response
- Intranasal (research and Russian clinical use)
- Subcutaneous injection (research)
Evidence Summary
Each peptide has Russian clinical use and a limited published record, mostly outside international peer review. The combination has no controlled trial data.
Human clinical evidence
- Russian studies report cognitive and anxiolytic effects for each peptide separately, generally small and with limited methodological reporting.
- No controlled human study of the combination has been identified.
Animal studies
- Rodent work reports increased BDNF expression with Semax and anxiolytic-like behaviour with Selank.
Anecdotal / community information
- Nootropic community reports dominate English-language information about this stack.
Reported Adverse Events in Research
- Nasal irritation is reported with intranasal use.
- Headache, fatigue and irritability are reported anecdotally.
- No systematic international safety dataset exists for either peptide, or for the blend.
Limitations of Current Evidence
- Most supporting literature is Russian-language and has not been independently replicated.
- Blinding and endpoint reporting in the available studies are frequently inadequate.
- Blended vials prevent independent adjustment of each peptide.
Why It Is Used
- Cognitive
Focus, Mood and Cognitive Load
Two Russian-developed peptides used together for the same reason people pair a stimulant with an anxiolytic: attention without the edge.
Read the case study
Research References
- Animal study
Semax: ACTH(4-10) analogue and BDNF expression
- Clinical trial
Selank: tuftsin analogue and anxiolytic activity